1
|
Moffitt GB, Sandison GA, Argento DC, Emery R, Wootton LS, Parvathaneni U, Liao JJ, Laramore GE, Stewart RD. Effects of tissue heterogeneity and comparisons of collapsed cone and Monte Carlo fast neutron patient dosimetry using the University of Washington clinical neutron therapy system (CNTS). Phys Med Biol 2023; 68:245011. [PMID: 37983905 DOI: 10.1088/1361-6560/ad0e38] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 11/20/2023] [Indexed: 11/22/2023]
Abstract
Fast neutron therapy is a high linear energy transfer (LET) radiation treatment modality offering advantages over low LET radiations. Multileaf collimator technology reduces normal-tissue dose (toxicity) and makes neutron therapy more comparable to MV x-ray treatments. Published clinical-trial and other experiences with fast neutron therapy are reported. Early comparative studies failed to consider differences in target-dose spatial conformality between x-ray and neutron treatments, which is especially important for organs-at-risk close to tumor targets. Treatments planning systems (TPS) for high-energy neutrons lag behind TPS tools for MV x-rays, creating challenges for comparative studies of clinical outcomes. A previously published Monte Carlo model of the University of Washington (UW) Clinical Neutron Therapy System (CNTS) is refined and integrated with the RayStation TPS as an external dose planning/verification tool. The collapsed cone (CC) dose calculations in the TPS are based on measured dose profiles and output factors in water, with the absolute dose determined using a tissue-equivalent ionization chamber. For comparison, independent (external) Monte Carlo simulation computes dose on a voxel-by-voxel basis using an atlas that maps Hounsfield Unit (HU) numbers to elemental composition and density. Although the CC algorithm in the TPS accurately computes neutron dose to water compared to Monte Carlo calculations, calculated dose to water differs from bone or tissue depending largely on hydrogen content. Therefore, the elemental composition of tissue and bone, rather than the material or electron density, affects fast neutron dose. While the CC algorithm suffices for reproducible patient dosimetry in fast neutron therapy, adopting methods that consider tissue heterogeneity would enhance patient-specific neutron dose accuracy relative to national standards for other types of ionizing radiation. Corrections for tissue composition have a significant impact on absolute dose and the relative biological effectiveness (RBE) of neutron treatments compared to other radiation types (MV x-rays, protons, and carbon ions).
Collapse
Affiliation(s)
- Gregory B Moffitt
- University of Washington School of Medicine, Department of Radiation Oncology, 1959 NE Pacific Street, Box 356043, Seattle, WA 98195, United States of America
| | - George A Sandison
- University of Washington School of Medicine, Department of Radiation Oncology, 1959 NE Pacific Street, Box 356043, Seattle, WA 98195, United States of America
| | - David C Argento
- University of Washington School of Medicine, Department of Radiation Oncology, 1959 NE Pacific Street, Box 356043, Seattle, WA 98195, United States of America
| | - Robert Emery
- University of Washington School of Medicine, Department of Radiation Oncology, 1959 NE Pacific Street, Box 356043, Seattle, WA 98195, United States of America
| | - Landon S Wootton
- University of Washington School of Medicine, Department of Radiation Oncology, 1959 NE Pacific Street, Box 356043, Seattle, WA 98195, United States of America
- Baylor Scott and White, Department of Radiation Oncology, 4516 Monterosa Lane, Round Rock, TX 78665, United States of America
| | - Upendra Parvathaneni
- University of Washington School of Medicine, Department of Radiation Oncology, 1959 NE Pacific Street, Box 356043, Seattle, WA 98195, United States of America
| | - Jay J Liao
- University of Washington School of Medicine, Department of Radiation Oncology, 1959 NE Pacific Street, Box 356043, Seattle, WA 98195, United States of America
| | - George E Laramore
- University of Washington School of Medicine, Department of Radiation Oncology, 1959 NE Pacific Street, Box 356043, Seattle, WA 98195, United States of America
| | - Robert D Stewart
- University of Washington School of Medicine, Department of Radiation Oncology, 1959 NE Pacific Street, Box 356043, Seattle, WA 98195, United States of America
| |
Collapse
|
2
|
Paul MB, Ankan AD, Deb H, Ahasan MM. A Monte Carlo simulation model to determine the effective concrete materials for fast neutron shielding. Radiat Phys Chem Oxf Engl 1993 2022. [DOI: 10.1016/j.radphyschem.2022.110476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
3
|
Moffitt GB, Wootton LS, Hårdemark B, Sandison GA, Laramore GE, Parvathaneni U, Stewart RD. Scattering kernels for fast neutron therapy treatment planning. Phys Med Biol 2020; 65:165009. [DOI: 10.1088/1361-6560/ab9a85] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
4
|
Datta NR, Bodis S. Hyperthermia with photon radiotherapy is thermoradiobiologically analogous to neutrons for tumors without enhanced normal tissue toxicity. Int J Hyperthermia 2020; 36:1073-1078. [PMID: 31709846 DOI: 10.1080/02656736.2019.1679895] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
The depth dose profiles of photons mirror those of fast neutrons. However, in contrast to the high linear energy transfer (LET) characteristics of neutrons; photons exhibit low LET features. Hyperthermia (HT) inhibits the repair of radiation-induced DNA damage and is cytotoxic to the radioresistant hypoxic tumor cells. Thus, thermoradiobiologically, HT simulates high LET radiation with photons. At temperatures of 39-45 °C, the physiological vasodilation allows rapid heat dissipation from normal tissues. On the contrary, the chaotic and relatively rigid tumor vasculature results in heat retention leading to higher intratumoural temperatures. Consequently, the high LET attributes of HT with photon radiations are mostly limited to the confines of the heated tumor while the normothermic normal tissues would be irradiated with low LET photons. HT thereby augments photon therapy by conferring therapeutic advantages of high LET radiations to the tumors akin to neutrons, while the 'heat-sink' effect spares the normal tissues from thermal radiosensitization. Thus, photon thermoradiotherapy imparts radiobiological advantages selectively to tumors analogous to neutrons without exaggerating normal tissue morbidities. The later has been the major concern with clinical fast neutron beam therapy. Outcomes reported from several clinical trials in diverse tumor sites add testimony to the enhanced therapeutic efficacy of photon thermoradiotherapy.
Collapse
Affiliation(s)
- Niloy Ranjan Datta
- Department of Radiation Oncology, KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland
| | - Stephan Bodis
- Department of Radiation Oncology, KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland.,Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
5
|
Abstract
Purpose: Neutrons were an active field of radiobiology at the time of publication of the first issues of the International Journal of Radiation Biology in 1959. Three back-to-back papers published by Neary and his colleagues contain key elements of interest at the time. The present article aims to put these papers into context with the discovery of the neutron 27 years previously and then give a feel for how the field has progressed to the present day. It does not intend to provide a comprehensive review of this enormous field, but rather to provide selective summaries of main driving forces and developments. Conclusions: Neutron radiobiology has continued as a vigorous field of study throughout the past 84 years. Main driving forces have included concern for protection from the harmful effects of neutrons, exploitation and optimization for cancer therapy (fast beam therapy, brachytherapy and boron capture therapy), and scientific curiosity about the mechanisms of radiation action. Effort has fluctuated as the emphasis has shifted from time to time, but all three areas remain active today. Whatever the future holds for the various types of neutron therapy, the health protection aspects will remain with us permanently because of natural environmental exposure to neutrons as well as increased additional exposures from a variety of human activities.
Collapse
|
6
|
Wang T, Long J, Wang S, Yang Z, Li J, Huang G, Zhang L, Jian Yang A, Renshaw Wang X. Diffusion and distribution of deuterium in scandium deuteride thin films under irradiation of deuterium ion beam. Sci Rep 2017; 7:13304. [PMID: 29042591 PMCID: PMC5645373 DOI: 10.1038/s41598-017-13780-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Accepted: 09/29/2017] [Indexed: 11/20/2022] Open
Abstract
Scandium deuteride (ScDx) thin films, as an alternative target for deuterium-deuterium (D-D) reaction, are a very important candidate for detection and diagnostic applications. Albeit with their superior thermal stability, the ignorance of the stability of ScDx under irradiation of deuterium ion beam hinders the realization of their full potential. In this report, we characterize ScDx thin films with scanning electron microscopy (SEM) and X-ray diffraction (XRD), Rutherford backscattering spectroscopy (RBS) and elastic recoil detection analysis (ERDA). We found with increased implantation of deuterium ions, accumulation and diffusion of deuterium are enhanced. Surprisingly, the concentration of deuterium restored to the value before implantation even at room temperature, revealing a self-healing process which is of great importance for the long-term operation of neutron generator.
Collapse
Affiliation(s)
- Tao Wang
- Institute of Fluid Physics, CAEP, P. O. Box 919-106, Mianyang, 621900, China. .,School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, 230026, China.
| | - Jidong Long
- Institute of Fluid Physics, CAEP, P. O. Box 919-106, Mianyang, 621900, China
| | - Shiwei Wang
- School of Sino-Russian, Heilongjiang University, Harbin, 150000, China
| | - Zhen Yang
- Institute of Fluid Physics, CAEP, P. O. Box 919-106, Mianyang, 621900, China
| | - Jie Li
- Institute of Fluid Physics, CAEP, P. O. Box 919-106, Mianyang, 621900, China
| | - Gang Huang
- Institute of Fluid Physics, CAEP, P. O. Box 919-106, Mianyang, 621900, China
| | - Linwen Zhang
- Institute of Fluid Physics, CAEP, P. O. Box 919-106, Mianyang, 621900, China
| | - Allen Jian Yang
- Division of Physics and Applied Physics, School of Physical and Mathematical Sciences, Nanyang Technological University, Singapore, 637371, Singapore.
| | - Xiao Renshaw Wang
- Division of Physics and Applied Physics, School of Physical and Mathematical Sciences, Nanyang Technological University, Singapore, 637371, Singapore.,School of Electrical and Electronic Engineering, Nanyang Technological University, Singapore, 639798, Singapore
| |
Collapse
|
7
|
Gold nanoparticles as a potent radiosensitizer in neutron therapy. Oncotarget 2017; 8:112390-112400. [PMID: 29348833 PMCID: PMC5762518 DOI: 10.18632/oncotarget.19837] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Accepted: 07/25/2017] [Indexed: 01/03/2023] Open
Abstract
The purpose of this study was to investigate the potential of gold nanoparticles as radiosensitizer for use in neutron therapy against hepatocellular carcinoma. The hepatocellular carcinoma cells lines Huh7 and HepG2 were irradiated with γ and neutron radiation in the presence or absence of gold nanoparticles. Effects were evaluated by transmission electron microscopy, cell survival, cell cycle, DNA damage, migration, and invasiveness. Gold nanoparticles significantly enhanced the radiosensitivity of Huh7 and HepG2 cells to γ-rays by 1.41- and 1.16-fold, respectively, and by 1.80- and 1.35-fold to neutron radiation, which has high linear energy transfer. Accordingly, exposure to neutron radiation in the presence of gold nanoparticles induced cell cycle arrest, DNA damage, and cell death to a significantly higher extent, and suppressed cell migration and invasiveness more robustly. These effects are presumably due to the ability of gold nanoparticles to amplify the effective dose from neutron radiation more efficiently. The data suggest that gold nanoparticles may be clinically useful in combination therapy against hepatocellular carcinoma by enhancing the toxicity of radiation with high linear energy transfer.
Collapse
|
8
|
Liao JJ, Parvathaneni U, Laramore GE, Thompson JA, Bhatia S, Futran ND, Bhrany AD, Hawes SE, Ladra M. Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. Head Neck 2014; 36:1162-7. [PMID: 23852725 DOI: 10.1002/hed.23428] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2012] [Revised: 04/07/2013] [Accepted: 06/27/2013] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Primary head and neck mucosal melanomas (HNMMs) are rare tumors managed with surgery and/or radiotherapy and associated with poor outcomes. Given their radioresistance, high linear energy transfer radiotherapy with neutrons may improve local control. METHODS We conducted a retrospective review of 14 patients with HNMM treated with neutrons at the University of Washington from 1990 to 2012. Five patients had T3 disease, 9 had T4 disease, 3 had regional nodal disease, and 4 had distant metastases at diagnosis. Primary sites were sinonasal (n=10), lip (n=2), and palate (n=2). Ten patients had initial surgical resection/debulking. RESULTS Nine patients had gross residual disease, 6 had complete response, and 3 had partial response. Local control was achieved in 79% until death or last follow-up, and 50% developed distant metastases. Kaplan-Meier 5-year local control was 66% and overall survival was 21%. CONCLUSION High rates of locoregional control were achieved with neutrons, despite the presence of gross disease. Survival was limited by early distant metastases.
Collapse
Affiliation(s)
- Jay J Liao
- University of Washington, Department of Radiation Oncology, Seattle, Washington
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Mizoe JE, Hasegawa A, Jingu K, Takagi R, Bessyo H, Morikawa T, Tonoki M, Tsuji H, Kamada T, Tsujii H, Okamoto Y. Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol 2012; 103:32-7. [DOI: 10.1016/j.radonc.2011.12.013] [Citation(s) in RCA: 109] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2010] [Revised: 11/11/2011] [Accepted: 12/28/2011] [Indexed: 02/03/2023]
|
10
|
Abstract
Tumour hypoxia is one of the limiting factors in obtaining tumour control in radiotherapy. The high-LET region of a beam of heavy charged particles such as carbon ions is located in the distal part of the Bragg peak. A modulated or spread out Bragg peak (SOBP) is a weighted function of several Bragg peaks at various energies, which however results in a dilution of the dose-average LET in the target volume. Here, we investigate the possibility to redistribute the LET by dedicated treatment plan optimisation, in order to maximise LET in the target volume. This may be a strategy to potentially overcome hypoxia along with dose escalation or dose painting. The high-LET region can be shaped in very different ways, while maintaining the distribution of the absorbed dose or biological effective dose. Treatment plans involving only carbon ion beams, show very different LET distributions depending on how the fields are arranged. Alternatively, a LET boost can be applied in multi-modal treatment planning, such as combining carbon ions with protons and/or photons. For such mixed radiation modalities, significant "LET boosts" can be achieved at nearly arbitrary positions within the target volume. Following the general understanding of the relationship between hypoxia, LET and the oxygen enhancement ratio (OER), we conclude, that an additional therapeutic advantage can be achieved by confining the high-LET part of the radiation in hypoxic compartments of the tumour, and applying low-LET radiation to the normoxic tissue. We also anticipate that additional advantages may be achieved by deliberate sparing of normal tissue from high LET regions. Consequently, treatment planning based on simultaneous dose and LET optimisation has a potential to achieve higher tumour control and/or reduced normal tissue control probability (NTCP).
Collapse
Affiliation(s)
- Niels Bassler
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark.
| | | | | | | |
Collapse
|
11
|
Kiger JL, Kiger WS, Riley KJ, Binns PJ, Patel H, Hopewell JW, Harling OK, Busse PM, Coderre JA. Functional and Histological Changes in Rat Lung after Boron Neutron Capture Therapy. Radiat Res 2008; 170:60-9. [DOI: 10.1667/rr1266.1] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2007] [Accepted: 02/29/2008] [Indexed: 11/03/2022]
|
12
|
Daşu A, Toma-Daşu I. What is the Clinically Relevant Relative Biologic Effectiveness? A Warning for Fractionated Treatments With High Linear Energy Transfer Radiation. Int J Radiat Oncol Biol Phys 2008; 70:867-74. [PMID: 17889448 DOI: 10.1016/j.ijrobp.2007.07.2358] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2007] [Revised: 07/04/2007] [Accepted: 07/06/2007] [Indexed: 11/21/2022]
Abstract
PURPOSE To study the clinically relevant relative biologic effectiveness (RBE) of fractionated treatments with high linear energy transfer (LET) radiation and to identify the important factors that might influence the transfer of tolerance and curative levels from low LET radiation. These are important questions in the light of the growing interest for the therapeutic use of radiation with higher LET than electrons or photons. METHODS AND MATERIALS The RBE of various fractionated schedules was analyzed with theoretical models for radiation effect, and the resulting predictions were compared with the published clinical and experimental data regarding fractionated irradiation with high LET radiation. RESULTS The clinically relevant RBE increased for greater doses per fraction, in contrast to the predictions from single-dose experiments. Furthermore, the RBE for late-reacting tissues appeared to modify more quickly than that for early-reacting tissues. These aspects have quite important clinical implications, because the increased biologic effectiveness reported for this type of radiation would otherwise support the use of hypofractionation. Thus, the differential between acute and late-reacting tissues could put the late-reacting normal tissues at more risk from high LET irradiation; however, at the same time, it could increase the therapeutic window for slow-growing tumors. CONCLUSIONS The modification of the RBE with the dose per fraction must be carefully taken into consideration when devising fractionated treatments with high LET radiation. Neglecting to do so might result in an avalanche of complications that could obscure the potential advantages of the therapeutic use of this type of radiation.
Collapse
Affiliation(s)
- Alexandru Daşu
- Department of Radiation Physics, Norrland University Hospital, Umeå, Sweden.
| | | |
Collapse
|
13
|
Mizoe JE, Tsujii H, Hasegawa A, Yanagi T, Takagi R, Kamada T, Tsuji H, Takakura K. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69:390-6. [PMID: 17459607 DOI: 10.1016/j.ijrobp.2007.03.003] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2007] [Revised: 03/01/2007] [Accepted: 03/05/2007] [Indexed: 11/18/2022]
Abstract
PURPOSE To report the results of a Phase I/II clinical trial for patients with malignant gliomas, treated with combined X-ray radiotherapy (XRT), chemotherapy, and carbon ion radiotherapy (CRT). METHODS AND MATERIALS Between October 1994 and February 2002, 48 patients with histologically confirmed malignant gliomas (16 anaplastic astrocytoma (AA) and 32 glioblastoma multiforme (GBM) were enrolled in a Phase I/II clinical study. The treatment involved the application of 50 Gy/25 fractions/5 weeks of XRT, followed by CRT at 8 fractions/2 weeks. Nimustine hydrochloride (ACNU) were administered at a dose of 100 mg/m(2) concurrently in weeks 1, 4, or 5 of XRT. The carbon ion dose was increased from 16.8 to 24.8 Gray equivalent (GyE) in 10% incremental steps (16.8, 18.4, 20.0, 22.4, and 24.8 GyE, respectively). RESULTS There was no Grade 3 or higher acute reaction in the brain. The late reactions included four cases of Grade 2 brain morbidity and four cases of Grade 2 brain reaction among 48 cases. The median survival time (MST) of AA patients was 35 months and that of GBM patients 17 months (p = 0.0035). The median progression-free survival and MST of GBM showed 4 and 7 months for the low-dose group, 7 and 19 months for the middle-dose group, and 14 and 26 months for the high-dose group. CONCLUSION The results of combined therapy using XRT, ACNU chemotherapy, and CRT showed the potential efficacy of CRT for malignant gliomas in terms of the improved survival rate in those patients who received higher carbon doses.
Collapse
Affiliation(s)
- Jun-Etsu Mizoe
- Hospital, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Jereczek-Fossa BA, Krengli M, Orecchia R. Particle beam radiotherapy for head and neck tumors: radiobiological basis and clinical experience. Head Neck 2006; 28:750-60. [PMID: 16804876 DOI: 10.1002/hed.20448] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Head and neck tumors are often located near critical organs, making it impossible to deliver a dose of conventional radiotherapy high enough to eradicate the disease. Our aim was to review the potential benefits and available clinical experience of particle beam therapy (hadrontherapy) in the treatment of these tumors. METHODS A review of the literature was carried out through a MEDLINE search (publications between 1980 and 2005). RESULTS A review of the available clinical data shows that particle beam therapy can offer several radiobiological and physical advantages over conventional photon radiotherapy: improved dose distribution permits dose escalation within the target and optimal sparing of normal tissue. Preclinical and clinical studies suggest that there may be benefits to using hadrontherapy for tumors characterized by poor radiosensitivity and critical location. At present, the most used hadrons are protons and, as yet on an experimental basis, carbon ions. It is now well accepted that there are certain indications for using proton therapy for skull base tumors (chordoma and chondrosarcoma), paranasal sinus carcinomas, selected nasopharyngeal tumors, and neutron/ion therapy for salivary gland carcinomas (in particular, adenoid cystic tumors). Its viability in other cases, such as locally advanced squamous cell carcinoma, melanoma, soft tissue sarcoma, and bone sarcoma, is still under investigation. CONCLUSIONS Hadrontherapy can be beneficial in the treatment of tumors characterized by poor radiosensitivity and critical location. Further clinical and radiobiological studies are warranted for improved selection of patient population.
Collapse
|
15
|
Mizoe JE, Tsujii H, Kamada T, Matsuoka Y, Tsuji H, Osaka Y, Hasegawa A, Yamamoto N, Ebihara S, Konno A. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 60:358-64. [PMID: 15380567 DOI: 10.1016/j.ijrobp.2004.02.067] [Citation(s) in RCA: 122] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2003] [Revised: 02/20/2004] [Accepted: 02/26/2004] [Indexed: 11/21/2022]
Abstract
PURPOSE To evaluate the toxicity and efficacy of carbon ion radiotherapy for head-and-neck cancer in a Phase I/II dose escalation clinical trial. METHODS AND MATERIALS Between June 1994 and January 1997, 36 patients with locally advanced, histologically proven, and new or recurrent cancer of the head and neck were treated with carbon ions. A dose escalation study was conducted, delivering 18 fractions through 6 weeks for 17 patients (Group A) and 16 fractions through 4 weeks for 19 patients (Group B). Eligibility and ineligibility criteria were the same in both groups. The dosages were escalated in increments of 10% after careful observation of at least 3 patients treated with the same dosages. The endpoints of the study were a Grade 3 reaction of the skin and the mucous membrane or local control of the tumors. RESULTS Follow-up time ranged from 77 to 108 months with a median of 90 months. Grade 3 acute reaction of the skin was detected in 1 of the 2 patients in Group A who were treated with 70.2 GyE/18 fractions/6 weeks. In Group B, Grade 3 acute skin reaction was detected in 20% (1/5), 27% (2/11), and 67% (2/3) patients treated with 52.8 GyE, 57.6 GyE, and 64.0 GyE through 16 fractions for 4 weeks, respectively. There was only 1 patient with a Grade 3 acute reaction of the mucous membrane. Only 1 patient developed a Grade 2 late reaction of the mucous membrane (superficial ulcer), which was located close to the tumor. No other Grade 2 or greater late reaction was noted until the time of analysis. Acute tumor reactions in 34 patients consisted of 10 patients of complete response 19 of partial response, 4 of no change, and 1 of progressive disease. Local control of 34 patients calculated by the Kaplan-Meier method was 75% at 5 years. Five years' local control of five malignant melanomas showed 100%, and that of 9 patients with adenoid cystic carcinoma was 90%. Also, local control of 8 patients of salivary glands and 4 patients of ears was 100% at 56 months and 5 years. CONCLUSIONS The dose fractionation methods of 70.2 GyE through 18 fractions for 6 weeks and 64.0 GyE through 16 fractions for 4 weeks showed equal clinical outcome in terms of morbidity and local control. The outcome of carbon ion radiotherapy showed a specific effectiveness in local control of non-squamous cell carcinoma such as adenoid cystic carcinomas and malignant melanomas. From the results of this study, it can be concluded that carbon ion radiotherapy will deliver a high local control rate without unacceptable injuries to the surrounding normal tissues.
Collapse
Affiliation(s)
- Jun-Etsu Mizoe
- Hospital, Research Center of Charged Particle, National Institute of Radiological Sciences, Chiba, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Nikoghosyan A, Schulz-Ertner D, Didinger B, Jäkel O, Zuna I, Höss A, Wannenmacher M, Debus J. Evaluation of therapeutic potential of heavy ion therapy for patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58:89-97. [PMID: 14697425 DOI: 10.1016/s0360-3016(03)01439-1] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE To investigate the feasibility of raster scanned heavy charged particle therapy in the treatment of prostate cancer (PCa,) with special regard to the influence of internal organ motion on the dose distribution. METHODS AND MATERIALS The CT data of 8 patients with PCa who underwent three-dimensional conformal radiotherapy (RT) were chosen. In addition to the routine treatment planning scan, three to five additional positioning control CT scans were performed. The organs at risk and the target volumes were defined on all CT scans. Primary and boost carbon ion plans were calculated to deliver 66 Gy to the clinical target volume/planning target volume, with an additional 10 Gy to the gross tumor volume (GTV). To estimate the influence of internal organ motion on plan quality, the dose was recalculated on the basis of the control CT scans. The comparative analysis was based on the dose-volume histogram-derived physical parameters. RESULTS The average 90% target coverage was 99.1% for the GTV. The maximal dose to the rectum was 71.8 Gy. The average rectal mean dose was 19 Gy. The volume of the rectum receiving 70 and 68 Gy was 0.1 and 0.3 cm3. The average difference in the 90% coverage for the GTV on control CT cubes was 3.6%. The maximal rectal dose increased to 76.2 Gy. The deviation in the mean rectal dose was <1 Gy on average. The rectal volume receiving 70 and 68 Gy increased to 2.5 and 3.3 cm3. CONCLUSION The investigation demonstrated the feasibility of raster scanned carbon ions for PCa RT. Excellent coverage of the target volume and optimal sparing of the rectum were acquired. The combination of photon intensity-modulated RT and a carbon ion boost to the GTV is the most rational solution for the gain of clinical experience in heavy ion RT for PCa patients.
Collapse
Affiliation(s)
- Anna Nikoghosyan
- Division of Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Noël G, Feuvret L, Ferrand R, Mazeron JJ. Le traitement par neutrons : hadronthérapie partie II : bases physiques et expérience clinique. Cancer Radiother 2003; 7:340-52. [PMID: 14522355 DOI: 10.1016/s1278-3218(03)00113-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Neutrons have radiobiological characteristics, which differ from those of conventional radiotherapy beams (photons) and which offer a theoretical advantage over photons to fight radioresistance by the differential relative biological effect of them between normal and tumour tissues. Neutron therapy beneficed of great interest between 1975 and 1985. Many of phase III trials were conducted and indications have been definitively deducted of them. After briefly describing the properties of neutron beams, this review discusses the indication of neutron therapy on the basis of the clinical results. Salivary, prostate tumours and sarcomas are the main indications of neutron therapy. In concern to the prostate cancers, other alternative treatments reduce the neutron therapy field. For sarcomas, the lack of randomised trials limits the impact of the interest of neutrons. For other tumours, the ratio benefice/risk of neutron therapy is inferior to these obtained with photons and they could not be considered like classical indications.
Collapse
Affiliation(s)
- G Noël
- Centre de protonthérapie d'Orsay (CPO), BP 65, 91402 cedex, Orsay, France
| | | | | | | |
Collapse
|
18
|
Britten RA, Peters LJ, Murray D. Biological factors influencing the RBE of neutrons: implications for their past, present and future use in radiotherapy. Radiat Res 2001; 156:125-35. [PMID: 11448233 DOI: 10.1667/0033-7587(2001)156[0125:bfitro]2.0.co;2] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The recent resurgence of interest in fast-neutron therapy, particularly for the treatment of prostate cancer, warrants a review of the original radiobiological basis for this modality and the evolution of these concepts that resulted from subsequent experimentation with the fast-neutron beams used for randomized clinical trials. It is clear from current radiobiological knowledge that some of the postulates that formed the mechanistic basis for past clinical trials were incorrect. Such discrepancies, along with the inherent physical disadvantages of neutron beams in terms of collimation and intensity modulation, may partially account for the lack of therapeutic benefit observed in many randomized clinical trials. Moreover, it is equally apparent that indiscriminate prescription of fast-neutron therapy is likely to lead to an adverse clinical outcome in a proportion of patients. Hence any renewed efforts to establish a niche for this modality in clinical radiation oncology will necessitate the development of a triage system that can discriminate those patients who might benefit from fast-neutron therapy from those who might be harmed by it. In the future, fast-neutron therapy might be prescribed based upon the relative status of appropriate molecular parameters that have a differential impact upon radiosensitivity to photons compared to fast neutrons.
Collapse
Affiliation(s)
- R A Britten
- Department of Oncology, University of Alberta, and Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada
| | | | | |
Collapse
|
19
|
Pignol JP, Slabbert J. Recoil proton, alpha particle, and heavy ion impacts on microdosimetry and RBE of fast neutrons: analysis of kerma spectra calculated by Monte Carlo simulation. Can J Physiol Pharmacol 2001. [DOI: 10.1139/y00-088] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Fast neutrons (FN) have a higher radio-biological effectiveness (RBE) compared with photons, however the mechanism of this increase remains a controversial issue. RBE variations are seen among various FN facilities and at the same facility when different tissue depths or thicknesses of hardening filters are used. These variations lead to uncertainties in dose reporting as well as in the comparisons of clinical results. Besides radiobiology and microdosimetry, another powerful method for the characterization of FN beams is the calculation of total proton and heavy ion kerma spectra. FLUKA and MCNP Monte Carlo code were used to simulate these kerma spectra following a set of microdosimetry measurements performed at the National Accelerator Centre. The calculated spectra confirmed major classical statements: RBE increase is linked to both slow energy protons and alpha particles yielded by (n,α) reactions on carbon and oxygen nuclei. The slow energy protons are produced by neutrons having an energy between 10 keV and 10 MeV, while the alpha particles are produced by neutrons having an energy between 10 keV and 15 MeV. Looking at the heavy ion kerma from <15 MeV and the proton kerma from neutrons <10 MeV, it is possible to anticipate y* and RBE trends.Key words: fast neutron, kerma, microdosimetry, RBE, Monte Carlo.
Collapse
|
20
|
Pignol J, Slabbert J, Binns P. Monte Carlo simulation of fast neutron spectra: mean lineal energy estimation with an effectiveness function and correlation to RBE. Int J Radiat Oncol Biol Phys 2001; 49:251-60. [PMID: 11163522 DOI: 10.1016/s0360-3016(00)01406-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE Intercomparisons of radiotherapy trials conducted at different fast neutron facilities are complicated by the dependence of the relative biologic effectiveness (RBE) of the different beams on the fast neutrons spectra. To obtain a better understanding of the influence of neutron energy on radiation quality, Monte Carlo simulations were performed to calculate fast neutron (FN) spectra at different irradiation positions. To allow for comparisons with experimental data, the positions were chosen to be the same as that used by other investigators to obtain microdosimetry readings and radiobiological data. METHODS AND MATERIALS The primary neutron yield for beryllium targets bombarded with protons at the National Accelerator Center, Louvain, Nice, and Orleans facilities were calculated using the FLUKA code. Neutron transport simulations were performed with MCNP-4A, giving FN spectra for various phantom depths, hardening filter thickness, and field sizes. Using an effectiveness function, FN energy groups were correlated with mean lineal energies (y*-values) obtained experimentally by other workers. RESULTS Calculations confirm earlier measurements that a decrease in beam quality by a hardening filter is the result of a reduction in the low-energy neutron component, i.e., neutrons below 3 MeV. Variations in RBE due to changes in field size and different phantom depths could also be explained by variations of neutrons with energies between 3-15 MeV. The effectiveness function allows one to calculate changes in y* observed for the NAC beam with great accuracy (R(2) = 0.99, p < 0.0001). Also, when this function is applied to beams with different neutron energies, y* calculated values show a very significant correlation with measured RBE values (R(2) = 0.98, p < 0.0001). CONCLUSION The effectiveness function appears to be suitable to predict changes in y*-values and variations in RBE, using FN spectra simulated for various neutron therapy facilities.
Collapse
Affiliation(s)
- J Pignol
- Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada.
| | | | | |
Collapse
|
21
|
Söderberg J, Carlsson GA. Fast neutron absorbed dose distributions in the energy range 0.5-80 meV--a Monte Carlo study. Phys Med Biol 2000; 45:2987-3007. [PMID: 11049184 DOI: 10.1088/0031-9155/45/10/317] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Neutron pencil-beam absorbed dose distributions in phantoms of bone, ICRU soft tissue, muscle, adipose and the tissue substitutes water, A-150 (plastic) and PMMA (acrylic) have been calculated using the Monte Carlo code FLUKA in the energy range 0.5 to 80 MeV. For neutrons of energies < or = 20 MeV, the results were compared to those obtained using the Monte Carlo code MCNP4B. Broad-beam depth doses and lateral dose distributions were derived. Broad-beam dose distributions in various materials were compared using two kinds of scaling factor: a depth-scaling factor and a dose-scaling factor. Build-up factors due to scattered neutrons and photons were derived and the appropriate choice of phantom material for determining dose distributions in soft tissue examined. Water was found to be a good substitute for soft tissue even at neutron energies as high as 80 MeV. The relative absorbed doses due to photons ranged from 2% to 15% for neutron energies 10-80 MeV depending on phantom material and depth. For neutron energies below 10 MeV the depth dose distributions derived with MCNP4B and FLUKA differed significantly, the difference being probably due to the use of multigroup transport of low energy (< 19.6 MeV) neutrons in FLUKA. Agreement improved with increasing neutron energies up to 20 MeV. At energies > 20 MeV, MCNP4B fails to describe dose build-up at the phantom interface and penumbra at the edge of the beam because it does not transport secondary charged particles. The penumbra width, defined as the distance between the 80% and 20% iso-dose levels at 5 cm depth and for a 10 x 10 cm2 field, was between 0.9 mm and 7.2 mm for neutron energies 10-80 MeV.
Collapse
Affiliation(s)
- J Söderberg
- Department of Radiation Physics, IMV, Faculty of Health Sciences, Linköping University, Sweden.
| | | |
Collapse
|
22
|
Marunick MT, Donat TL, Ahmad S, Jacobs JR. Total maxillary osteoradionecrosis after adjuvant neutron radiotherapy: a clinical report. J Prosthet Dent 1998; 79:617-20. [PMID: 9627888 DOI: 10.1016/s0022-3913(98)70066-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- M T Marunick
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University, Detroit, Mich., USA
| | | | | | | |
Collapse
|
23
|
Orecchia R, Zurlo A, Loasses A, Krengli M, Tosi G, Zurrida S, Zucali P, Veronesi U. Particle beam therapy (hadrontherapy): basis for interest and clinical experience. Eur J Cancer 1998; 34:459-68. [PMID: 9713294 DOI: 10.1016/s0959-8049(97)10044-2] [Citation(s) in RCA: 73] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The particle or hadron beams deployed in radiotherapy (protons, neutrons and helium, carbon, oxygen and neon ions) have physical and radiobiological characteristics which differ from those of conventional radiotherapy beams (photons) and which offer a number of theoretical advantages over conventional radiotherapy. After briefly describing the properties of hadron beams in comparison to photons, this review discusses the indications for hadrontherapy and analyses accumulated experience on the use of this modality to treat mainly neoplastic lesions, as published by the relatively few hadrontherapy centres operating around the world. The analysis indicates that for selected patients and tumours (particularly uveal melanomas and base of skull/spinal chordomas and chondrosarcomas), hadrontherapy produces greater disease-free survival. The advantages of hadrontherapy are most promisingly realised when used in conjunction with modern patient positioning, radiation delivery and focusing techniques (e.g. on-line imaging, three-dimensional conformal radiotherapy) developed to improve the efficacy of photon therapy. Although the construction and running costs of hadrontherapy units are considerably greater than those of conventional facilities, a comprehensive analysis that considers all the costs, particularly those resulting from the failure of less effective conventional radiotherapy, might indicate that hadrontherapy could be cost effective. In conclusion, the growing interest in this form of treatment seems to be fully justified by the results obtained to date, although more efficacy and dosing studies are required.
Collapse
Affiliation(s)
- R Orecchia
- Radiotherapy Division, Istituto Europeo di Oncologia, Milano, Italy
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Breteau N, Schlienger M, Favre A, Lescrainier J, Touboul E, Stecken J, Heitzmann A. Fast neutrons in the treatment of grade IV astrocytomas. BULLETIN DU CANCER. RADIOTHERAPIE : JOURNAL DE LA SOCIETE FRANCAISE DU CANCER : ORGANE DE LA SOCIETE FRANCAISE DE RADIOTHERAPIE ONCOLOGIQUE 1996; 83 Suppl:135s-41s. [PMID: 8949766 DOI: 10.1016/0924-4212(96)84899-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In 1981, the Hôpital Tenon group and the Orléans neutron therapy team initiated a collaborative study for the treatment of grade IV astrocytomas using a combination of photons and neutrons. Neutrons were used as boost in a reduced volume. Doses were progressively increased from 6 to 7 Gy and later up to 8 Gy. Since October 1994, a neutron boost of 7.5 Gy has been delivered. At the time of evaluation, 294 patients had a minimum follow-up of 12 months. Univariate analysis indicated that clinical status, tumor location and photon fractionation scheme had no significant influence on survival. In contrast, age, surgical procedure and neutron dose were found to be prognostic factors. In a multivariate analysis, the prognostic value of the surgical procedure disappeared and the only remaining independent prognostic factors up to 11 months after treatment (P = 0.001) were age and the neutron dose. As far as neutron dose was concerned, survival increased with dose from 6 to 7 Gy up to 15 months. However, after 15 months, there was no longer any benefit in survival for the patients treated with 8 Gy, and complications related to overdosage began to appear. There was a long-term survival group: 55 patients were alive 18 months after treatment (18%). The median survival was 26.7 months. The best survival was observed for patients treated with a neutron boost of 7 Gy in eight fractions over 11 days (25 vs 18%). The present study demonstrates the feasibility of a combination of photons (30 Gy total brain) followed by a neutron boost (7 Gy) in the treatment of high-grade astrocytomas. The results are in good agreement with the published data. In the literature, age and surgical procedure are currently considered as the most important prognostic factors. The prevalence of neutron dose over these two other prognostic factors, as shown in this study, is an important additional argument in favor of the use of neutrontherapy in the management of these tumors. A possible benefit when combining external fast neutrontherapy with boron neutron capture therapy (BNCT) could reasonably be expected.
Collapse
Affiliation(s)
- N Breteau
- CHRO Hôpital de La Source, Orléans, France
| | | | | | | | | | | | | |
Collapse
|
25
|
Courdi A, Brassart N, Herault J, Mari D, Chauvel P. The RBE of fast neutrons for in vitro inactivation of human tumour cells determined by the ratio of mean inactivation doses. Acta Oncol 1996; 35:237-42. [PMID: 8639321 DOI: 10.3109/02841869609098507] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
In an effort to clarify the relationship between sensitivity of human tumour cells to low-LET and to fast neutron irradiation, 10 human tumour cell lines were exposed to cobalt gamma-rays and to 60 MeV (p -> Be+) neutron beam. The data were pooled with results of 31 human tumour cell lines previously published. The analysis of date using the linear-quadratic model indicated that not only alpha values increased after neutron irradiation, but so did beta values too, although to a lesser extent. The mean inactivation dose (MID) was derived for each cell line from the linear-quadratic parameters after low-LET and high-LET exposure. MID values following neutron irradiation were closely correlated to those after gamma-ray irradiation. In these 41 cell lines, the extreme values of RBE derived by the ratio of MID varied by a factor of 3 among the cell lines. RBE was positively correlated to photon MID, meaning that intrinsically radiation resistant tumour cells have a higher neutron RBE, on average. Similar findings were observed if alpha ratios were used instead of MID ratios. In addition, the RBE/dose variations were more marked in cells with the higher RBE. Taken together, these data suggest that, although considerable variations exist among human tumour cell lines, intrinsically radioresistant cells are relatively more sensitized when exposed to high LET beams than radioresponsive tumours. An 'intrinsic gain factor' may thus be expected in irradiating radiation resistant tumours with fast neutrons, in addition to the hypoxic or kinetic gain factors. Because the quadratic component is still present after neutron irradiation, we suggest using MID ratio as a reference RBE when comparing survival curves of cells exposed to radiations of different qualities.
Collapse
Affiliation(s)
- A Courdi
- Centre Antoine-Lacassagne, Biomedical Cyclotron, Nice, France
| | | | | | | | | |
Collapse
|